News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Repros Therapeutics Inc. (RPRX) Provides Clinical Update for Androxal® Phase 3 Program



9/13/2012 9:37:26 AM

THE WOODLANDS, Texas, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX)today provided a clinical update of its Androxal® Phase 3 program.

Pivotal Phase 3 Studies

Repros has randomized the first subjects in ZA-301, the first of two pivotal studies. The study is being conducted at various US clinical sites.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES